<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="fbxl4-mtddepl" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">fbxl4-mtddepl</book-part-id>
      <title-group>
        <title><italic toggle="yes">FBXL4</italic>-Related Encephalomyopathic Mitochondrial DNA Depletion Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonyms: Mitochondrial DNA Depletion Syndrome 13 (MTDPS13), Encephalomyopathic Type; FBXL4 Deficiency; <italic toggle="yes">FBXL4</italic>-Related Early-Onset Mitochondrial Encephalopathy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Almannai</surname>
            <given-names>Mohammed</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Medical Biochemical Genetics Fellow, Department of Molecular &#x00026;s Human Genetics<break/>Baylor College of Medicine<break/>Houston, Texas</aff>
          <email>almannai@bcm.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dai</surname>
            <given-names>Hongzheng</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Clinical Molecular Genetics and Genomics Fellow, Department of Molecular &#x00026; Human Genetics<break/>Baylor College of Medicine<break/>Houston, Texas</aff>
          <email>hongzheng.dai@bcm.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>El-Hattab</surname>
            <given-names>Ayman W</given-names>
          </name>
          <degrees>MD, FAAP, FACMG</degrees>
          <aff>Medical Genetics and Metabolic Consultant, Division of Clinical Genetics and Metabolic Disorders<break/>Pediatric Department<break/>Tawam Hospital<break/>Al-Ain, United Arab Emirates</aff>
          <email>elhattabaw@yahoo.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wong</surname>
            <given-names>Lee-Jun C</given-names>
          </name>
          <degrees>PhD, FACMG</degrees>
          <aff>Professor, Department of Molecular and Human Genetics<break/>Baylor College of Medicine</aff>
          <email>ljwong@bcm.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>6</day>
          <month>4</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="fbln5-cutis-laxa" document-type="chapter">
<italic toggle="yes">FBLN5</italic>-Related Cutis Laxa</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="craniosynostosis" document-type="chapter">
<italic toggle="yes">FGFR</italic>-Related Craniosynostosis Syndromes</related-object>
      <abstract id="fbxl4-mtddepl.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">FBXL4</italic>-related encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome is a multi-system disorder characterized primarily by congenital or early-onset lactic acidosis and growth failure, feeding difficulty, hypotonia, and global developmental delay. Other neurologic manifestations can include seizures, movement disorders, ataxia, autonomic dysfunction, and stroke-like episodes. All affected individuals alive at the time they were reported (median age: 3.5 years) demonstrated significant global developmental delay. Other findings can involve the heart (hypertrophic cardiomyopathy, congenital heart malformations, arrhythmias), liver (mildly elevated transaminases), eyes (cataract, strabismus, nystagmus, optic atrophy), hearing (sensorineural hearing loss), and bone marrow (neutropenia, lymphopenia). Survival varies; the median age of reported deaths was two years (range 2 days - 75 months), although surviving individuals as old as 36 years have been reported. To date <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome has been reported in 50 individuals.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome is established in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">FBXL4</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management is best provided by a multidisciplinary team including neurology, nutrition, clinical genetics/metabolism, and developmental pediatrics. Other specialties may be involved as needed. To date no definite treatment is available; thus, treatment is mainly supportive: assuring adequate nutrition and standard treatment of neurologic complications including developmental delay/intellectual disability, seizures, cardiac complications, eye involvement, and hearing loss. Administration of cofactors and antioxidants, used in mitochondrial disorders with (generally) limited evidence of benefit, may be considered.</p>
          <p><italic toggle="yes">Surveillance:</italic> No surveillance guidelines have been published. The treating physician should decide about the frequency of follow up of eyes, hearing, heart, feeding difficulties, liver, neurologic complications, and neutropenia based on the patient&#x02019;s findings.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome is inherited in an autosomal recessive manner. When both parents are heterozygous carriers, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier (heterozygote), and a 25% chance of being unaffected and not a carrier. Once the <italic toggle="yes">FBXL4</italic> pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic diagnosis are possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="fbxl4-mtddepl.Diagnosis">
        <title>Diagnosis</title>
        <sec id="fbxl4-mtddepl.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">FBXL4</italic>-related encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome <bold>should be suspected</bold> in individuals with early-onset (often congenital) lactic acidosis along with a combination of the following clinical features, brain MRI findings, and supportive laboratory findings.</p>
          <p>
            <bold>Clinical features</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Developmental delay. Often global with severe speech impairment and lack of ambulation</p>
            </list-item>
            <list-item>
              <p>Neurologic findings, Hypotonia, seizures, movement disorders, such as ataxia, autonomic dysfunction</p>
            </list-item>
            <list-item>
              <p>Feeding difficulty and failure to thrive</p>
            </list-item>
            <list-item>
              <p>Abnormal growth. Intrauterine growth restriction, short stature, microcephaly (congenital and acquired)</p>
            </list-item>
            <list-item>
              <p>Cardiovascular abnormalities. Hypertrophic cardiomyopathy, congenital heart malformations, arrhythmia, pulmonary hypertension</p>
            </list-item>
          </list>
          <p>
            <bold>Brain MRI findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>White matter abnormalities (19/32 individuals reported). T<sub>2</sub>-weighted hyperintensities, delayed or poor myelination, and leukodystrophic changes</p>
            </list-item>
            <list-item>
              <p>Cerebral atrophy (14/32). Progressive; could be evident as early as age three months [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>]</p>
            </list-item>
            <list-item>
              <p>Basal ganglia abnormalities, including lesions and abnormal signal intensities (11/32)</p>
            </list-item>
            <list-item>
              <p>Pervientricular cysts (9/32)</p>
            </list-item>
            <list-item>
              <p>Thin corpus callosum (6/32)</p>
            </list-item>
            <list-item>
              <p>Cerebellar hypoplasia (6/32)</p>
            </list-item>
            <list-item>
              <p>Arachnoid cysts (4/32)</p>
            </list-item>
            <list-item>
              <p>Brain stem atrophy (4/32)</p>
            </list-item>
            <list-item>
              <p>Stroke-like episodes (1/32) [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.ebrahimifakhari.2015.549">Ebrahimi-Fakhari et al 2015</xref>]</p>
            </list-item>
          </list>
          <p>Only one child (who died at age 20 months) was reported to have a normal brain MRI [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>].</p>
          <p>MR spectroscopy may show high lactate peak in the brain and cerebrospinal fluid [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Persistently elevated lactate levels (range: 3-21 mmol/L; median: 13 mmol/L) were observed in all individuals. When assayed, cerebrospinal fluid lactate levels were also elevated [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
            </list-item>
            <list-item>
              <p>Hyperammonemia is seen in about 50% of individuals. Although ammonia levels close to 500 &#x003bc;mol/L have been reported [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>], the mean level was 141 &#x003bc;mol/L, median level 99 &#x003bc;mol/L, and range 30-485 &#x003bc;mol/L.</p>
            </list-item>
            <list-item>
              <p>Mild to moderate elevations in creatine kinase were reported in six of 13 individuals in one study [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>Muscle tissue and skin fibroblasts show [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.morton.2016">Morton et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>]:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Variably reduced mtDNA content (range: 10%-70%; mean: ~30% of tissue- and age-matched controls); and</p>
                </list-item>
                <list-item>
                  <p>Decreased activity of multiple complexes on electron transport chain activity assay in 80% of affected individuals. There is usually combined, though variable, deficiency of all complexes.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Muscle histology can show fiber size variability, lipid and glycogen accumulation, and variable reduction in COX activity. Enlarged and structurally altered mitochondria can be seen on electron microscopy [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="fbxl4-mtddepl.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome <bold>is established</bold> in a proband by identification of biallelic pathogenic variants in <italic toggle="yes">FBXL4</italic> on molecular genetic testing (see <xref ref-type="table" rid="fbxl4-mtddepl.T.molecular_genetic_testin">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include a combination of <bold>gene-targeted testing</bold> (multi-gene panel or single-gene testing) and <bold>genomic testing</bold> (comprehensive genome sequencing) depending on the phenotype.</p>
          <p>Gene-targeted testing requires the clinician to determine which gene(s) are likely involved, whereas genomic testing may not. Children with the suggestive clinical, laboratory, and neuroimaging findings could be diagnosed using gene-targeted testing (see <xref ref-type="sec" rid="fbxl4-mtddepl.Option_1">Option 1</xref>), whereas those with clinical features indistinguishable from many other mitochondrial disorders are more likely to be diagnosed using genomic testing (see <xref ref-type="sec" rid="fbxl4-mtddepl.Option_2">Option 2</xref>).</p>
          <sec id="fbxl4-mtddepl.Option_1">
            <title>Option 1</title>
            <p>When the clinical, laboratory, and brain MRI findings suggest the diagnosis of <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome, molecular genetic testing approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">FBXL4</italic> is performed first. If only one pathogenic variant is found, gene-targeted deletion/duplication analysis could be considered; however, to date no exonic or whole gene deletions have been reported.</p>
              </list-item>
              <list-item>
                <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">FBXL4</italic> and other genes related to mtDNA depletion syndromes (see <xref ref-type="sec" rid="fbxl4-mtddepl.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of condition at the most reasonable cost while limiting secondary findings. Of note, given the rarity of <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome some panels for mtDNA depletion syndromes may not include this gene. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
                <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
              </list-item>
            </list>
          </sec>
          <sec id="fbxl4-mtddepl.Option_2">
            <title>Option 2</title>
            <p>When the phenotype is indistinguishable from many other mitochondrial disorders molecular genetic testing approaches can include a combination of <bold>genomic testing</bold> (comprehensive genome sequencing) or <bold>gene-targeted testing</bold> (multi-gene panel):</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Comprehensive genome sequencing</bold> (when available) includes exome sequencing and genome sequencing [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.wortmann.2015.437">Wortmann et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>]. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
              </list-item>
              <list-item>
                <p><bold>A multi-gene panel</bold> for inherited mitochondrial disorders may also be considered.</p>
              </list-item>
            </list>
            <table-wrap id="fbxl4-mtddepl.T.molecular_genetic_testin" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in <italic toggle="yes">FBXL4</italic>-Related mtDNA Depletion Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">FBXL4</italic>
                    </td>
                    <td headers="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50/50&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_fbxl4-mtddepl.T.molecular_genetic_testin_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">None reported to date</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="fbxl4-mtddepl.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="fbxl4-mtddepl" object-id="fbxl4-mtddepl.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="fbxl4-mtddepl.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="fbxl4-mtddepl.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="fbxl4-mtddepl.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="fbxl4-mtddepl.TF.1.4">
                  <label>4. </label>
                  <p><xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al [2013]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al [2013]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al [2015]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al [2016]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al [2016]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.morton.2016">Morton et al [2016]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al [2016]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.van_rij.2016.425">van Rij et al [2016]</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al [2017]</xref></p>
                </fn>
                <fn id="fbxl4-mtddepl.TF.1.5">
                  <label>5. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="fbxl4-mtddepl.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="fbxl4-mtddepl.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome has been reported in 50 individuals to date [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.morton.2016">Morton et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.van_rij.2016.425">van Rij et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>]. It mainly presents as congenital lactic acidosis along with developmental delay, other neurologic manifestations, feeding difficulty, growth failure, and variable involvement of other organs.</p>
          <p><bold>Age of onset</bold> was soon after birth in the majority of reported individuals (median age of onset: one day; range 1 day - 13 years). Only five individuals presented after age six months, including a female presenting at age 13 years [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>].</p>
          <p>In two children, the disease presented prenatally: one male was born at 26 weeks&#x02019; gestation following preterm labor resulting from polyhydramnios that was believed to be due to hypotonia and decreased fetal movement [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.van_rij.2016.425">van Rij et al 2016</xref>]; another male was delivered at 34 weeks&#x02019; gestation due to prenatally diagnosed supraventricular tachycardia [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
          <p>The common clinical manifestations summarized in <xref ref-type="table" rid="fbxl4-mtddepl.T.clinical_manifestations">Table 2</xref> are discussed below the table.</p>
          <table-wrap id="fbxl4-mtddepl.T.clinical_manifestations" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Clinical Manifestations of <italic toggle="yes">FBXL4</italic>-Related mtDNA Depletion Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Clinical Manifestation</th>
                  <th id="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Frequency</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Neurologic</bold>
                  </td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <bold>50/50 (100%)</bold>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Developmental delay</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>45/45 (100%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Hypotonia</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>39/42 (93%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Seizures</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>14/42 (33%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Movement disorders&#x000a0;<sup>1</sup></p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>5/17 (29%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Ataxia</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>4/15 (27%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Autonomic dysfunction</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>3/12 (25%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Stroke-like episodes</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>1/32 (3%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">
                    <bold>Growth</bold>
                  </td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Failure to thrive</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>25/33 (76%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>IUGR</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>18/31 (58%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Short stature</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>17/31 (55%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Microcephaly (congenital and acquired)</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>14/36 (39%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">
                    <bold>Gastrointestinal</bold>
                  </td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Feeding difficulties</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>27/31 (87%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Hepatopathy</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>8/24 (33%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Cardiac</bold>
                  </td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <bold>20/37 (54%)</bold>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Cardiomyopathy</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>10/37 (27%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Congenital heart malformations</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>7/37 (19%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Arrhythmia</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>6/41 (15%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Pulmonary hypertension</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>4/37 (11%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Ophthalmologic</bold>
                  </td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <bold>20/30 (67%)</bold>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Cataract</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>5/30 (17%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Strabismus</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>5/31 (16%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Nystagmus</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>6/30 (20%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Optic atrophy</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>3/30 (10%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">
                    <bold>Other</bold>
                  </td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Neutropenia</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>8/43 (19%)</p></list-item></list>
</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Hearing impairment</p></list-item></list>
</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.clinical_manifestations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>4/33 (12%)</p></list-item></list>
</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>IUGR = intrauterine growth restriction, defined as birth weight &#x0003c;10<sup>th</sup> centile</p>
              </fn>
              <fn id="fbxl4-mtddepl.TF.2.1">
                <label>1. </label>
                <p>Movement disorders reported include dystonia, choreoathetosis, hyperkinetic movements, and tremors [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Neurologic.</bold> Developmental delay is usually global, associated with severe speech impairment and lack of ambulation in the majority of reported cases. All affected individuals alive at the time they were reported (age range: 1 month - 36 years; median age: 3.5 years) demonstrated significant global developmental delay [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
          <p>Hypotonia is severe and early onset, often presenting in the neonatal period.</p>
          <p>Seizures started at age four months in one infant [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>]. Seizure types reported include complex partial seizures [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>] and absence and generalized seizures [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>].</p>
          <p>Other less commonly reported neurologic manifestations for which clinical information is available include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Movement disorders including hyperkinetic movements [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>], dystonia and choreoathetosis [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>], and tremors [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>];</p>
            </list-item>
            <list-item>
              <p>Recurrent stroke-like episodes starting at age ten years in a girl who was reported at age 13 years [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.ebrahimifakhari.2015.549">Ebrahimi-Fakhari et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>].</p>
            </list-item>
          </list>
          <p><bold>Gastrointestinal manifestations.</bold> Feeding difficulties are a major problem for most individuals with <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome. Factors contributing to the feeding difficulties include hypotonia, gastroesophageal reflux disease, frequent vomiting, and swallowing dysfunction. Recurrent aspiration was reported in six individuals [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>]. Many require nasogastric tube feeding or gastrostomy.</p>
          <p>Hepatopathy manifests as mildly elevated transaminases. Liver failure has not been reported to date. Of note, one individual with baseline mild increases in transaminases experienced further increase in liver enzymes following initiation of a ketogenic diet (initiated due to initial suspicion of pyruvate dehydrogenase deficiency) [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>].</p>
          <p><bold>Cardiac.</bold> Cardiomyopathy, the most common cardiac manifestation, is typically hypertrophic. Left ventricular non-compaction was reported in one individual [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>].</p>
          <p>Congenital heart malformations include atrial septal defect, ventricular septal defect, patent foramen ovale, patent ductus arteriosus, tricuspid regurgitation, and tetralogy of Fallot (TOF). Other than TOF, the reported cardiac malformations are either relatively common or physiologic, bringing into question whether these are true associations or chance occurrences.</p>
          <p>Arrhythmias include supraventricular tachycardia and Wolff-Parkinson-White syndrome [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
          <p><bold>Ophthalmologic.</bold> Cataract was congenital in three individuals [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>].</p>
          <p>Other reported eye findings include nystagmus and optic atrophy [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.morton.2016">Morton et al 2016</xref>].</p>
          <p><bold>Immunologic.</bold> Neutropenia was either episodic or persistent. Neutropenia appeared to predispose to infections and poor wound healing [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>].</p>
          <p>One individual had lymphopenia and hypogammaglobulinemia in addition to neutropenia [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>].</p>
          <p>Even without neutropenia, some individuals were prone to recurrent infections which in some cases resulted in metabolic decompensation and death [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>].</p>
          <p><bold>Distinctive facial features.</bold> About 70% of affected individuals have some variable distinctive facial features, including the following: thick eyebrows, short, upslanted palpebral fissures with epicanthus, broad nasal bridge, bulbous nasal tip, and smooth and long philtrum.</p>
          <p>
            <bold>Less frequently reported manifestations</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Respiratory distress, likely due to hypotonia and weak muscles, was reported in six individuals [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
            </list-item>
            <list-item>
              <p>Sensorineural hearing impairment was reported in four individuals [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.morton.2016">Morton et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
            </list-item>
            <list-item>
              <p>Other uncommon features include renal tubular acidosis (5 individuals), progressive scoliosis (2 individuals), non-specified exercise intolerance (4 individuals), and sleep dysfunction.</p>
            </list-item>
            <list-item>
              <p>Several males had hypospadias and/or cryptorchidism. One male had hypoplastic scrotum [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>One individual developed exocrine pancreatic deficiency [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>].</p>
            </list-item>
          </list>
          <p><bold>Prognosis.</bold>
<italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome is associated with a high rate of death in childhood: 43% (20 of 47) of reported children are deceased; seven died early in infancy. The median age of death was two years (range 2 days - 75 months). The 27 individuals alive at the time that they were reported ranged in age from one month to 36 years (median age: 3.5 years). Because of the small number of reported individuals, it is possible (indeed, likely) that the published literature is biased towards more severe cases and, thus, the full clinical spectrum (and prognosis) is yet to be appreciated.</p>
        </sec>
        <sec id="fbxl4-mtddepl.GenotypePhenotype_Correlat">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations are known.</p>
        </sec>
        <sec id="fbxl4-mtddepl.Prevalence">
          <title>Prevalence</title>
          <p><italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome is rare; the exact prevalence is unknown.</p>
          <p>To date, 50 affected individuals from different ethnic groups &#x02013; including Arabs, persons of northern European heritage, and Latin Americans/Hispanics &#x02013; have been reported [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.morton.2016">Morton et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.van_rij.2016.425">van Rij et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
          <p>Consanguinity was reported in 64% of cases.</p>
        </sec>
      </sec>
      <sec id="fbxl4-mtddepl.Genetically_Related_Alleli">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with biallelic pathogenic variants in <italic toggle="yes">FBXL4</italic>.</p>
      </sec>
      <sec id="fbxl4-mtddepl.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome needs to be differentiated from other mtDNA depletion syndromes, a genetically and clinically heterogeneous group of autosomal recessive disorders that are characterized by a severe reduction in mtDNA content leading to impaired energy production in affected tissues and organs.</p>
        <p>Mitochondrial DNA depletion syndromes occur as a result of defects in mtDNA maintenance caused by pathogenic variants in nuclear genes that function in either mitochondrial nucleotide synthesis (e.g., <italic toggle="yes">TK2</italic>, <italic toggle="yes">SUCLA2</italic>, <italic toggle="yes">SUCLG1</italic>, <italic toggle="yes">RRM2B</italic>, <italic toggle="yes">DGUOK</italic>, and <italic toggle="yes">TYMP</italic>) or mtDNA replication (e.g., <italic toggle="yes">POLG</italic> and <italic toggle="yes">TWNK</italic>). The function of <italic toggle="yes">FBXL4</italic> is not yet known.</p>
        <p>Mitochondrial DNA depletion syndromes are phenotypically classified into myopathic, encephalomyopathic, hepatocerebral, and neurogastrointestinal forms (<xref ref-type="table" rid="fbxl4-mtddepl.T.mitochondrial_dna_deplet">Table 3</xref>) [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.elhattab.2013.186">El-Hattab &#x00026; Scaglia 2013</xref>].</p>
        <p><bold>Myopathic forms</bold> present in infancy or early childhood with hypotonia, proximal muscle weakness, and feeding difficulty. Cognition is usually spared. Typically, there is rapid progression of muscle weakness with respiratory failure and death within a few years of onset.</p>
        <p><bold>Encephalomyopathic mtDNA depletion syndromes</bold> present in infancy with hypotonia and global developmental delay. Depending on the underlying defect, other features, including deafness, movement disorders, Leigh like syndrome, and renal disease, can be observed.</p>
        <p><bold>Hepatocerebral forms</bold> present with early-onset liver dysfunction and neurologic involvement, including developmental delay, abnormal eye movements, and peripheral neuropathy.</p>
        <p><bold>Neurogastrointestinal</bold>
<bold>forms,</bold> the prototype of which is mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease, present in adolescence to early adulthood with progressive gastrointestinal dysmotility, cachexia, and peripheral neuropathy.</p>
        <table-wrap id="fbxl4-mtddepl.T.mitochondrial_dna_deplet" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Mitochondrial DNA Depletion Syndromes</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Phenotype&#x000a0;<sup>1</sup></th>
                <th id="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene</th>
                <th id="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mitochondrial DNA Depletion Syndrome #, Type</th>
                <th id="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference&#x000a0;<sup>2</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Hepatocerebral</bold>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">DGUOK</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3, hepatocerebral type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="dguok-mtddepl" document-type="chapter">Deoxyguanosine Kinase Deficiency</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">POLG</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4A, Alpers type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic>-Related Disorders</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">MPV17</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">6<italic toggle="yes">,</italic> hepatocerebral type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="mpv17-mtdep" document-type="chapter"><italic toggle="yes">MPV17</italic>-Related Hepatocerebral Mitochondrial DNA Depletion Syndrome</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1"><italic toggle="yes">TWNK</italic> (<italic toggle="yes">C10orf2)</italic></td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">7, hepatocerebral type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/271245">271245</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">TFAM</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">15, hepatocerebral type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://omim.org/entry/617156">617156</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_1" rowspan="6" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Encephalomyopathic</bold>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SUCLA2</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5, encephalomyopathic type w/methylmalonic aciduria</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="sucla2-def" document-type="chapter"><italic toggle="yes">SUCLA2</italic>-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic Form with Methylmalonic Aciduria</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">FBXL4</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">13, encephalomyopathic type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">FBXL4</italic>-Related Encephalomyopathic Mitochondrial DNA Depletion Syndrome</td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">SUCLG1</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">9, encephalomyopathic type with methylmalonic aciduria</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="suclg1-mtddepl" document-type="chapter"><italic toggle="yes">SUCLG1</italic>-related mtDNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">RRM2B</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">8A, encephalomyopathic type w/renal tubulopathy</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="rrm2b-mtddepl" document-type="chapter"><italic toggle="yes">RRM2B</italic>-Related Mitochondrial Disease</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">OPA1</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">14, encephalocardiomyopathic type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616896">616896</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">ABAT</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Encephalomyopathic type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613163">613163</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Neurogastrointestinal</bold>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TYMP</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1, MNGIE type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter">Mitochondrial Neurogastrointestinal Encephalopathy Disease</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">POLG</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4B, MNGIE type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic>-Related Disorders</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">RRM2B</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">8B, MNGIE type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="rrm2b-mtddepl" document-type="chapter"><italic toggle="yes">RRM2B</italic>-Related Mitochondrial Disease</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Myopathic</bold>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TK2</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2, myopathic type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="tk2-mtddepl" document-type="chapter"><italic toggle="yes">TK2</italic>-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form</related-object>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">AGK</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">10, cardiomyopathic type (Sengers syndrome)</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/212350">212350</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">MGME1</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">11, myopathic type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615084">615084</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <italic toggle="yes">SLC25A4</italic>
                </td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">12B, cardiomyopathic type</td>
                <td headers="hd_h_fbxl4-mtddepl.T.mitochondrial_dna_deplet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615418">615418</ext-link></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="fbxl4-mtddepl.TF.3.1">
              <label>1. </label>
              <p>Within each phenotypic category, mtDNA depletion syndromes are ordered by relative prevalence.</p>
            </fn>
            <fn id="fbxl4-mtddepl.TF.3.2">
              <label>2. </label>
              <p>See hyperlinked <italic toggle="yes">GeneReview</italic> or OMIM phenotype entry for more information.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="fbxl4-mtddepl.Management">
        <title>Management</title>
        <sec id="fbxl4-mtddepl.Evaluations_Following_Init">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of the disease and needs in an individual diagnosed with <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome, the evaluations following diagnosis (if not performed as part of the evaluation that led to diagnosis) listed in <xref ref-type="table" rid="fbxl4-mtddepl.T.recommended_evaluations">Table 4</xref> are recommended.</p>
          <table-wrap id="fbxl4-mtddepl.T.recommended_evaluations" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Recommended Evaluations Following Initial Diagnosis</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">System</th>
                  <th id="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Evaluation</th>
                  <th id="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Comment</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Eyes</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ophthalmologic evaluation</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">ENT</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hearing assessment</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiovascular</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Cardiac evaluation w/electrocardiogram &#x00026; echocardiography</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Consider referral to cardiology if results are abnormal</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Gastrointestinal</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Nutritional evaluation; swallowing assessment for feeding difficulties</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Evaluation of liver function w/AST/ALT, bilirubin, total protein, albumin, &#x00026; coagulation profile</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">Neurologic</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Neurology consultation including comprehensive neurologic examination</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Brain MRI to evaluate extent of the disease</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Electroencephalogram</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">If there is a history of seizures</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Immunologic</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Complete blood count to evaluate for neutropenia</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Consider more detailed immunologic evaluation if there is a history of recurrent infections</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Miscellaneous / Other</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Developmental evaluation to provide baseline level of functioning &#x00026; recommendations for services (speech, occupational, &#x00026; physical therapy)</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_evaluations_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Consultation w/a clinical geneticist and/or genetic counselor</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="fbxl4-mtddepl.Treatment_of_Manifestation">
          <title>Treatment of Manifestations</title>
          <p>Management is best provided by a multidisciplinary team including Neurology, Nutrition, Clinical Genetics/ Metabolism, and Developmental Pediatrics. Other specialties including Gastroenterology, Cardiology, Hematology, Immunology, Ophthalmology, and Nephrology may be involved based on the associated complications.</p>
          <p>No definite treatment is available to date; thus, treatment is mainly supportive (<xref ref-type="table" rid="fbxl4-mtddepl.T.treatment_of_manifestati">Table 5</xref>). Administration of cofactors and antioxidants, used in mitochondrial disorders with (generally) limited evidence of benefit, may be considered.</p>
          <table-wrap id="fbxl4-mtddepl.T.treatment_of_manifestati" orientation="portrait" position="anchor">
            <label>Table 5. </label>
            <caption>
              <p>Treatment of Manifestations in Individuals with <italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Manifestation</th>
                  <th id="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Treatment</th>
                  <th id="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Considerations/Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Inadequate nutrition</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">A nasogastric tube or gastrostomy tube are frequently needed due to feeding difficulties &#x00026; failure to thrive</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">In one affected child, improved nutrition resulted in improvement in hypogammaglobulinemia &#x00026; neutropenia&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Seizures</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Standard treatment w/antiepileptic drugs</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Immobility/wheelchair dependence</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consultation w/physical medicine &#x00026; rehabilitation (PM&#x00026;R) specialists to help w/mobility or assistive devices (e.g., wheelchair</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiomyopathy and arrhythmia</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Standard treatment per Cardiology recommendations</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Neutropenia</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consider granulocyte colony stimulating factor&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Significant acidosis</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consider bicarbonate therapy</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cataract and/or strabismus</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Surgical treatment if indicated</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hearing loss</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hearing aids</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.treatment_of_manifestati_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="fbxl4-mtddepl.TF.5.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al [2016]</xref>
                </p>
              </fn>
              <fn id="fbxl4-mtddepl.TF.5.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al [2015]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <sec id="fbxl4-mtddepl.Global_Developmental_Disab">
            <title>Global Developmental Disability / Intellectual Disability Educational Issues</title>
            <p><bold>Ages 0-3 years.</bold> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the United States, early intervention is a federally funded program available in all states.</p>
            <p><bold>Ages 3-5 years.</bold> In the United States, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed.</p>
            <p>
              <bold>Ages 5-21 years</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>In the United States, an IEP based on the individual&#x02019;s level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district until age 21.</p>
              </list-item>
              <list-item>
                <p>Discussion about transition plans including financial and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.</p>
              </list-item>
            </list>
            <p><bold>All ages.</bold> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. Some issues to consider:</p>
            <list list-type="bullet">
              <list-item>
                <p>Private supportive therapies based on the affected individual&#x02019;s needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p>
              </list-item>
              <list-item>
                <p>In the United States, Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</p>
              </list-item>
              <list-item>
                <p>In the United States, families with limited income and resources may also qualify for supplemental security income for their child with a disability.</p>
              </list-item>
            </list>
          </sec>
          <sec id="fbxl4-mtddepl.Motor_Dysfunction">
            <title>Motor Dysfunction</title>
            <p>
              <bold>Gross motor dysfunction</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Physical therapy is recommended to maximize mobility.</p>
              </list-item>
              <list-item>
                <p>Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</p>
              </list-item>
            </list>
            <p><bold>Fine motor dysfunction.</bold> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function (e.g., feeding, grooming, dressing, and writing).</p>
            <p><bold>Oral motor dysfunction.</bold> Assuming that the individual is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended for affected individuals who have difficulty feeding due to poor oral motor control.</p>
            <p><bold>Communication issues.</bold> Consider evaluation for alternative means of communication (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.asha.org/NJC/AAC/">Augmentative and Alternative Communication</ext-link>) for individuals who have expressive language difficulties.</p>
          </sec>
        </sec>
        <sec id="fbxl4-mtddepl.Prevention_of_Secondary_Co">
          <title>Prevention of Secondary Complications</title>
          <p>Regular immunization to prevent life-threatening infections is indicated.</p>
          <p>Antibiotic prophylaxis may be indicated for those with immunodeficiency [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>].</p>
        </sec>
        <sec id="fbxl4-mtddepl.Surveillance">
          <title>Surveillance</title>
          <p>No surveillance guidelines have been published. The following evaluations should be performed on a regular basis, with the treating physician determining the frequency based on initial presentation and severity of the condition.</p>
          <table-wrap id="fbxl4-mtddepl.T.recommended_surveillance" orientation="portrait" position="anchor">
            <label>Table 6. </label>
            <caption>
              <p>Recommended Surveillance for Individuals with <italic toggle="yes">FBXL4</italic>-Related mtDNA Depletion Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">System</th>
                  <th id="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Evaluation</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Eyes</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ophthalmologic evaluation</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">ENT/Mouth</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hearing evaluation</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiovascular</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Echocardiogram &#x00026; electrocardiogram to monitor for development of cardiomyopathy and/or arrhythmia, respectively</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Gastrointestinal</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Continued assessment of nutrition and growth</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Measurement of serum lactate, electrolytes, &#x00026; liver function tests w/AST/ALT, bilirubin, total protein, albumin, &#x00026; coagulation profile</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Neurologic</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Regular neurologic evaluations &#x00026; developmental assessments</td>
                </tr>
                <tr>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Immunologic</td>
                  <td headers="hd_h_fbxl4-mtddepl.T.recommended_surveillance_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Complete blood count</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="fbxl4-mtddepl.Evaluation_of_Relatives_at">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="fbxl4-mtddepl.Related_Genetic_Counseling">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="fbxl4-mtddepl.Therapies_Under_Investigat">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="fbxl4-mtddepl.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="fbxl4-mtddepl.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome is inherited in an autosomal recessive manner.</p>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are typically heterozygotes (i.e., carriers of one <italic toggle="yes">FBXL4</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In the (usual) instance in which both parents are carriers: at conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold>
<italic toggle="yes">FBXL4</italic>-related mtDNA depletion syndrome is typically lethal before reproductive age.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of an <italic toggle="yes">FBXL4</italic> pathogenic variant.</p>
        </sec>
        <sec id="fbxl4-mtddepl.Carrier_Heterozygote_Detec">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">FBXL4</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="fbxl4-mtddepl.Related_Genetic_Counseling">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="fbxl4-mtddepl.Prenatal_Testing_and_Preim">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">FBXL4</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="fbxl4-mtddepl.Resources">
        <title>Resources</title>
      </sec>
      <sec id="fbxl4-mtddepl.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">FBXL4</italic> comprises nine exons and spans 79 kb. See <related-object source-id="gene" document-id="fbxl4-mtddepl" object-id="fbxl4-mtddepl.molgen.TA">Table A</related-object>, <bold>Gene</bold> for a detailed summary of gene and protein information.</p>
        <p><bold>Pathogenic variants.</bold> About 50% of reported variants are missense; others include nonsense, splice site, and frame shift variants [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.huemer.2015.905">Huemer et al 2015</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bar_y.2016.342">Bar&#x000f8;y et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.pronicka.2016.174">Pronicka et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.van_rij.2016.425">van Rij et al 2016</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.dai.2017.634">Dai et al 2017</xref>].</p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">FBXL4</italic> encodes the F-box and leucine-rich repeat protein 4 (FBXL4) which localizes to the mitochondria via a mitochondrial targeting sequence [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>]. While the exact function of this protein is not known, it is believed to have an important role in mitochondrial maintenance. This is supported by findings in muscle tissue and/or skin fibroblasts from individuals with biallelic <italic toggle="yes">FBXL4</italic> pathogenic variants which showed decreased activity of multiple respiratory chain enzymes, disturbance of the mitochondrial network, loss of membrane potential, and variable depletion of mitochondrial DNA content [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.antoun.2016.1">Antoun et al 2016</xref>]. Of note, these biochemical defects were rescued by introduction of wild type <italic toggle="yes">FBXL4</italic> [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>].</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">FBXL4</italic> pathogenic variants result in loss of FBXL4 protein function, which in turn results in impaired mtDNA maintenance manifesting as mtDNA depletion and impaired energy production [<xref ref-type="bibr" rid="fbxl4-mtddepl.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="fbxl4-mtddepl.REF.gai.2013.482">Gai et al 2013</xref>].</p>
      </sec>
      <sec id="fbxl4-mtddepl.References">
        <title>References</title>
        <sec id="fbxl4-mtddepl.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="fbxl4-mtddepl.Literature_Cited.reflist0">
            <ref id="fbxl4-mtddepl.REF.antoun.2016.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Antoun</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McBride</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanstone</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naas</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michaud</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redpath</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMillan</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brophy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daoud</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraborty</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyment</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holcik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harper</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lines</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Detailed biochemical and bioenergetic characterization of FBXL4-related encephalomyopathic mitochondrial DNA depletion.</article-title>
                <source>JIMD Rep.</source>
                <year>2016</year>
                <volume>27</volume>
                <fpage>1</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">26404457</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.bonnen.2013.471">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonnen</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yarham</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faqeih</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Asmari</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saleh</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyaid</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadeel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simcox</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miwa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donti</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abu-Amero</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>93</volume>
                <fpage>471</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">23993193</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.bar_y.2016.342">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bar&#x000f8;y</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedurupillay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bliksrud</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigeland</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nedregaard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Str&#x000f8;mme</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frengen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misceo</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>A novel mutation in FBXL4 in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13.</article-title>
                <source>Eur J Med Genet.</source>
                <year>2016</year>
                <volume>59</volume>
                <fpage>342</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">27182039</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.dai.2017.634">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>VW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Hattab</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinawi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lines</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McNutt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gotway</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tian</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>FBXL4 defects are common in patients with congenital lactic acidemia and encephalomyopathic mitochondrial DNA depletion syndrome.</article-title>
                <source>Clin Genet.</source>
                <year>2017</year>
                <volume>91</volume>
                <fpage>634</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">27743463</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.ebrahimifakhari.2015.549">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ebrahimi-Fakhari</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seitz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;lker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                </person-group>
                <article-title>Recurrent stroke-like episodes in FBXL4-associated early-onset mitochondrial encephalomyopathy.</article-title>
                <source>Pediatr Neurol.</source>
                <year>2015</year>
                <volume>53</volume>
                <fpage>549</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">26421988</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.elhattab.2013.186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>El-Hattab</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.</article-title>
                <source>Neurotherapeutics.</source>
                <year>2013</year>
                <volume>10</volume>
                <fpage>186</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">23385875</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.gai.2013.482">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gai</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghezzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biagosch</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shamseldin</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reyes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukikawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheldon</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srinivasan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorza</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polyak</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Place</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Consugar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostrovsky</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sondheimer</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salih</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Jishi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raab</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bean</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furlan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konstantopoulou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huemer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierce</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkuraya</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>93</volume>
                <fpage>482</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">23993194</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.huemer.2015.905">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huemer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karall</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schossig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Jasmi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biagosch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Distelmaier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hauser</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertecant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebrahimi-Fakhari</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konstantopoulou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leydiker</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lourenco</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholl-B&#x000fc;rgi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilichowski</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>NI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnen</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutations.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2015</year>
                <volume>38</volume>
                <fpage>905</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">25868664</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.morton.2016">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>SU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neilan</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitz-Abe</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towne</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markianos</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prabhu</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agrawal</surname>
                    <given-names>PB</given-names>
                  </name>
                </person-group>
                <article-title>Hyperammonemia as a presenting feature in two siblings with FBXL4 variants.</article-title>
                <source>JIMD Rep.</source>
                <year>2016</year>
                <month>Nov</month>
                <day>18</day>
                <comment>Epub ahead of print</comment>
                <pub-id pub-id-type="pmid">27858371</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.pronicka.2016.174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pronicka</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piekutowska-Abramczuk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciara</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trubicka</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rokicki</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karkuci&#x00144;ska-Wi&#x00119;ckowska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajdowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jurkiewicz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosi&#x00144;ska</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rydzanicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stawinski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pronicki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krajewska-Walasek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x00142;oski</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>New perspective in diagnostics of mitochondrial disorders: two years' experience with whole-exome sequencing at a national paediatric centre.</article-title>
                <source>J Transl Med.</source>
                <year>2016</year>
                <volume>14</volume>
                <fpage>174</fpage>
                <pub-id pub-id-type="pmid">27290639</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.van_rij.2016.425">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Rij</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hellebrekers</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onkenhout</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendrickx</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gottschalk</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steggerda</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peeters-Scholte</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haak</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilhorst-Hofstee</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Polyhydramnios and cerebellar atrophy: a prenatal presentation of mitochondrial encephalomyopathy caused by mutations in the FBXL4 gene.</article-title>
                <source>Clin Case Rep.</source>
                <year>2016</year>
                <volume>4</volume>
                <fpage>425</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">27099744</pub-id>
              </element-citation>
            </ref>
            <ref id="fbxl4-mtddepl.REF.wortmann.2015.437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koolen</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Heuvel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Whole exome sequencing of suspected mitochondrial patients in clinical practice.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2015</year>
                <volume>38</volume>
                <fpage>437</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">25735936</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="fbxl4-mtddepl.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="fbxl4-mtddepl.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>6 April 2017 (bp) Review posted live</p>
            </list-item>
            <list-item>
              <p>6 October 2016 (ma) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
